Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Topiramate on Alcohol Use in Alcohol Dependent Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. DSM-IV Diagnosis of Alcohol Dependence; Minimal drinking level of 14 drinks per week for women and 20 drinks per week for men over a consecutive 30 day period during the last 90 days~2. Intent to stop drinking~3. Male or female age 18-65~4. Able to maintain sobriety for 3 consecutive days without the use of detoxification medications~5. Able to provide informed consent and to comprehend study procedures.~6. If a woman, then is willing to use an effective means of birth control during throughout the study period. These include: a. barrier (diaphragm or condom) with spermicide b.intrauterine progesterone contraceptive system c. levonorgestrel implant d. medroxyprogesterone acetate contraceptive injection e. complete abstinence~Exclusion Criteria:~1. Dependent on or extensive abuse of drugs or substances other than ethanol, nicotine, or caffeine as assessed by urine toxicology (2 out of 3 Dependent on or extensive abuse of drugs or substances other than positive consecutive urines)~2. DSM IV Axis I diagnoses other than ethanol, caffeine, or nicotine dependence severe enough to require treatment with medication or to prevent compliance with the protocol.~3. Currently being treated with disulfiram (Antabuse), naltrexone (ReVia), or acamprosate~4. Currently being treated with any other psychoactive or other CNS medications or a carbonic anhydrase inhibitor (e.g. acetazolamide)~5. In need of medical detoxification from alcohol.~6. Prior history of kidney stones.~7. History of liver disease. ALT or AST 3 times higher than upper range of normal values.~8. BUN or serum creatinine outside the normal range~9. Major neurological disorder including seizures~10. Other major diseases including severe hypertension, renal disease, or cardiac disease.~11. Prior participation within 60 days in another clinical study.~12. If female, a positive serum HCG or breast feeding.~13. If female using oral contraceptives as a means of birth control.~14. History of allergic sensitivity to topiramate~15. Pending imprisonment~16. Cardiac pacemaker or metal surgical implant.~17. History of angle closure glaucoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Topiramate Treatment (Type: ACTIVE_COMPARATOR): In this open label non-placebo controlled trial all subjects received topiramate, the active medication. Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM \& 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM \& 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM \& 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete